Lentistem® Biotech is an R&D centred medical biotechnology company which designs and produces therapeutic lentiviral vectors. Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells). Our team is working in collaboration with several hospitals, academic labs and government agencies in Spain to create cost-effective and precise advanced gene-based therapies. We also offer our expertise in lentiviral-based gene delivery systems to provide cutting-edge tools for basic research. The company has exclusive license to multiple technologies, which are currently being used in 18 labs worldwide and cited in more than 70 peer-reviewed scientific publications.
We have state-of-art facilities for molecular analysis, cell biology small animal research and cell-culture facilities with P2-level safety standards to produce the highest grade viral vectors.
Miguel García Toscano
Verónica Ayllón Cases
Juan Antonio Marchal
Juan José Díaz Mochón